600774 Hanshang Group
- 8.10
- -0.06-0.74%
Hanshang Group News
Hanshang Group Report for the Third Quarter of 2024
Hanshang Group\'s operating data announcement for the 1st to 3rd quarter of 2024
Hanshang Group's semi-annual report for 2024.
Hanshang Group's 2024 semi-annual report summary.
Hanshang Group (600774.SH): net income in the first half of the year was 8.5108 million yuan, a year-on-year decrease of 82.35%.
Hanshang Group (600774.SH) released its semi-annual report for 2024, with operating income of 626 million yuan, a 10.74% year-on-year decrease; net income attributable to shareholders of listed companies was 8.5108 million yuan, a YoY decrease of 82.35%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -4.0843 million yuan; basic earnings per share was 0.0288 yuan. The main factors affecting performance are: the impact of subsidiary Dikang Pharmaceutical on group procurement and rising prices of medicinal materials, which led to a decrease in profits; subsidiary Dikang Traditional Chinese Medicine Pharmaceutical resumed work and production this year.
Hanshang Group (600774.SH), some directors, supervisors, executives, and management personnel have collectively increased their shareholding by 0.7442 million shares.
Hanshang Group (600774.SH) announced that as of the disclosure date of the announcement, some directors, supervisors, and management personnel of the company...
Hanshang Group (600774.SH): The controlling shareholder has cumulatively increased its shareholding by 1.00%. The shareholding plan has been completed.
Hanshang Group (600774.SH) announced that its controlling shareholder, Zhuoer Holdings, accumulated a shareholding of 2.9504 million shares of the company's stock through the Shanghai Stock Exchange trading system via centralized bidding trading from April 29, 2024 to July 16, 2024, holding 1.00% of the company's issued shares, with an accumulated shareholding amount of 21.4928 million yuan. The shareholding plan has been fully implemented.
A-share anomaly | hanshang group fell more than 8%, medicinal material prices rose, and the net profit in the middle period is expected to decline by more than 80%.
On July 15th, Gelunhui reported that Hanshang Group (600774.SH) fell more than 8%, hitting a new 2-month low at 7.18 yuan, with a total market value of 2.12 billion yuan. The company issued a pre-reduction announcement yesterday evening, expecting that the net income for the first half of the year will be around 8 million yuan, a year-on-year decrease of about 83.41%. During the reporting period, the company's subsidiary, Chengdu Dikang Pharmaceutical Co., Ltd. was affected by factors such as group procurement and rising prices of medicinal materials, resulting in reduced profits.
Hanshang Group forecasts its half-year performance for 2024.
Hanshang Group (600774.SH) issued a profit warning, expecting a net income of approximately 8 million yuan in the first half of the year, a year-on-year decrease of about 83.41%.
Hanshang Group (600774.SH) released the performance forecast for the first half of 2024, and it is expected to have actual...
Express News | Hanshang Group: Currently, the production and operation activities are normal and there are no significant matters that should be disclosed but have not been disclosed.
Express News | Innovative drug concept shocks and rebounds, Hanshang Group hit the limit.
There were partial changes in medical and aesthetic concept stocks. The Kazakh Trifecta went up and down in a straight line, the Hanshang Group impacted the rise and fall, and many other stocks such as Shuyu Civic rallied in the short term.
There were partial changes in medical and aesthetic concept stocks. The Kazakh Trifecta went up and down in a straight line, the Hanshang Group impacted the rise and fall, and many other stocks such as Shuyu Civic rallied in the short term.
Express News | Hanshang Group: Plans to purchase 100% of Zheng An Industrial's shares and the “operating assets of the Wuhan Living Room Project” by issuing shares, etc.
Express News | The concept of assisted reproduction boosted Hanshang Group's rise and fall in early trading
The concept of medicine and beauty is Gao Kaiyue, Health, and Hanshang Group's bidding went up and down
The concept of medicine and beauty is open. Huaxi Biotech is over 14%, and Yuexin Health and Hanshang Group bid up and down. According to news, Guangdong is adjusting medical and aesthetic surgery programs, and cosmetic surgery can use injectable programs such as hyaluronic acid.
Changes in A-shares | Hanshang Group fell more than 5% in the past 4 days, falling 15% and was recently sold by Zhang Meng owners for more than 9 million
Gelonghui, May 15 | Hanshang Group (600774.SH) fell by more than 5% and fell 15% in the past 4 days. The current report is 769 yuan, with a total market value of 2.2 billion yuan. Previously, the stock fell to a standstill after rising and falling on the 2nd. According to data from the Dragon Tiger List, the famous Youji Securities League owner sold 9.132,700 yuan on the 10th. Furthermore, the company recently clarified that it is not currently engaged in stem cell treatment business.
Dragon Tiger List丨Hanshang Group fell to a standstill today, and the famous Travel and Investment Management League owner sold 9.132,700 yuan
Hanshang Group fell to a standstill today. According to data from the Dragon Tiger List, the sales department seats on the list traded 62.2462 million yuan throughout the day, accounting for 20.94% of the total transaction amount for the day. Among them, the purchase amount was 264.948 million yuan, and the sale amount was 35.7514 million yuan, with a total net sale of 9.256,500 yuan. Specifically, well-known investors appeared on the Dragon Tiger List. Zhang Mengzhu and Huatai Securities headquarters sold 9.1327 million yuan and 8.4629 million yuan respectively; the Beijing Anzhenmen Securities Sales Department of Cathay Pacific Junan Securities and Cathay Pacific Junan Securities Headquarters each bought 8.3823 million yuan and 5.9122 million yuan.
Is Hanshang Group Co., Ltd.'s (SHSE:600774) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Express News | Hanshang Group: The company is not currently engaged in stem cell therapy business
Analysis
Price Target
No Data
No Data